Juan Francisco Idiáquez, Rodrigo Salinas, Gabriel Cea
{"title":"智利吉兰-巴罗综合征发病率和死亡率(2013-2019年)。","authors":"Juan Francisco Idiáquez, Rodrigo Salinas, Gabriel Cea","doi":"10.1159/000547305","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Guillain-Barré syndrome (GBS) is a rare autoimmune disorder of the peripheral nervous system with incidence rates varying across regions. Based on hospital discharge data, this study aimed to analyze the incidence and mortality of GBS in Chile between 2013 and 2019.</p><p><strong>Methods: </strong>A retrospective review of GBS cases, identified using the ICD-10 code G61.0, was conducted using national hospital discharge records. The incidence rates were calculated annually and adjusted for the population. Demographic and clinical variables, including sex, age, insurance type, and outcomes, were analyzed.</p><p><strong>Results: </strong>A total of 1,696 cases were identified, yielding an annual incidence rate of 1.46 per 100,000 (95% CI: 1.28-2.64). Most cases occurred in males (58.8%), with a mean age of 46.62 years. The mortality rate was 1.7%, and the high survival rate was 98.3%.</p><p><strong>Conclusion: </strong>The incidence of GBS in Chile is comparable to the global rates, with a slight male predominance and a high survival rate. Further studies are warranted to explore the potential rurality and climatic factors influencing GBS incidence in Chile.</p>","PeriodicalId":54730,"journal":{"name":"Neuroepidemiology","volume":" ","pages":"1-7"},"PeriodicalIF":4.0000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503500/pdf/","citationCount":"0","resultStr":"{\"title\":\"Guillain-Barré Syndrome in Chile: Incidence and Mortality (2013-2019).\",\"authors\":\"Juan Francisco Idiáquez, Rodrigo Salinas, Gabriel Cea\",\"doi\":\"10.1159/000547305\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Guillain-Barré syndrome (GBS) is a rare autoimmune disorder of the peripheral nervous system with incidence rates varying across regions. Based on hospital discharge data, this study aimed to analyze the incidence and mortality of GBS in Chile between 2013 and 2019.</p><p><strong>Methods: </strong>A retrospective review of GBS cases, identified using the ICD-10 code G61.0, was conducted using national hospital discharge records. The incidence rates were calculated annually and adjusted for the population. Demographic and clinical variables, including sex, age, insurance type, and outcomes, were analyzed.</p><p><strong>Results: </strong>A total of 1,696 cases were identified, yielding an annual incidence rate of 1.46 per 100,000 (95% CI: 1.28-2.64). Most cases occurred in males (58.8%), with a mean age of 46.62 years. The mortality rate was 1.7%, and the high survival rate was 98.3%.</p><p><strong>Conclusion: </strong>The incidence of GBS in Chile is comparable to the global rates, with a slight male predominance and a high survival rate. Further studies are warranted to explore the potential rurality and climatic factors influencing GBS incidence in Chile.</p>\",\"PeriodicalId\":54730,\"journal\":{\"name\":\"Neuroepidemiology\",\"volume\":\" \",\"pages\":\"1-7\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503500/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuroepidemiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000547305\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroepidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547305","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
格林-巴罗综合征(GBS)是一种罕见的周围神经系统自身免疫性疾病,不同地区的发病率不同。基于出院数据,本研究旨在分析智利2013 - 2019年GBS的发病率和死亡率。方法:回顾性分析使用ICD-10代码G61.0识别的GBS病例,使用国家医院出院记录。发病率每年计算一次,并根据人群进行调整。分析了人口统计学和临床变量,包括性别、年龄、保险类型和结果。结果:共发现1696例,年发病率为1.46 / 10万(95% CI 1.28-2.64)。以男性居多(58.8%),平均年龄46.62岁。死亡率为1.7%,高生存率为98.3%。结论:智利GBS发病率与全球相当,男性略占优势,生存率较高。有必要进一步研究影响智利GBS发病率的潜在乡村和气候因素。
Guillain-Barré Syndrome in Chile: Incidence and Mortality (2013-2019).
Introduction: Guillain-Barré syndrome (GBS) is a rare autoimmune disorder of the peripheral nervous system with incidence rates varying across regions. Based on hospital discharge data, this study aimed to analyze the incidence and mortality of GBS in Chile between 2013 and 2019.
Methods: A retrospective review of GBS cases, identified using the ICD-10 code G61.0, was conducted using national hospital discharge records. The incidence rates were calculated annually and adjusted for the population. Demographic and clinical variables, including sex, age, insurance type, and outcomes, were analyzed.
Results: A total of 1,696 cases were identified, yielding an annual incidence rate of 1.46 per 100,000 (95% CI: 1.28-2.64). Most cases occurred in males (58.8%), with a mean age of 46.62 years. The mortality rate was 1.7%, and the high survival rate was 98.3%.
Conclusion: The incidence of GBS in Chile is comparable to the global rates, with a slight male predominance and a high survival rate. Further studies are warranted to explore the potential rurality and climatic factors influencing GBS incidence in Chile.
期刊介绍:
''Neuroepidemiology'' is the only internationally recognised peer-reviewed periodical devoted to descriptive, analytical and experimental studies in the epidemiology of neurologic disease. The scope of the journal expands the boundaries of traditional clinical neurology by providing new insights regarding the etiology, determinants, distribution, management and prevention of diseases of the nervous system.